Complete sequence of the 22q11.2 allele in 1,053 subjects with 22q11.2 deletion syndrome reveals modifiers of conotruncal heart defects by Zhao, Yingjie et al.
1 
 
Complete sequence of the 22q11.2 allele in 1,053 subjects with 22q11.2 deletion 
syndrome reveals modifiers of conotruncal heart defects  
 
Yingjie Zhao1, Alexander Diacou1, H. Richard Johnston2, Fadi I. Musfee3,  Donna M.McDonald-
McGinn4, Daniel McGinn4, T. Blaine Crowley4, Gabriela M. Repetto5, Ann Swillen6, Jeroen 
Breckpot6, Joris R. Vermeesch6, Wendy R. Kates7, M. Cristina Digilio8, Marta Unolt8,9, Bruno 
Marino9, Maria Pontillo10, Marco Armando10,11, Fabio Di Fabio9, Stefano Vicari10,12, Marianne van 
den Bree13, Hayley Moss13, Michael J. Owen13, Kieran C. Murphy14, Clodagh M. Murphy15, 
Declan Murphy15, Kelly Schoch16, Vandana Shashi16, Flora Tassone17, Tony J. Simon17, Robert 
J. Shprintzen18, Linda Campbell19, Nicole Philip20, Damian Heine-Suñer21, Sixto García-
Miñaúr22, Luis Fernández22, International 22q11.2 Brain and Behavior Consortium23, Carrie E. 
Bearden24, Claudia Vingerhoets25, Therese van Amelsvoort25, Stephan Eliez11, Maude 
Schneider11, Jacob Vorstman26, Doron Gothelf27, Elaine Zackai4, A.J Agopain3, Raquel E. Gur28, 
Anne S. Bassett29, Beverly S. Emanuel4, Elizabeth Goldmuntz30, Laura E. Mitchell3, Tao 
Wang31, Bernice E. Morrow1*  
 
 
1Department of Genetics, Albert Einstein College of Medicine, Bronx, NY, 10461, USA 
 
2Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, 
USA  
 
3Department of Epidemiology, Human Genetics and Environmental Sciences, UTHealth School 
of Public Health, Houston, Texas, 77225, USA  
 
2 
 
4Division of Human Genetics, Children’s Hospital of Philadelphia and Department of Pediatrics, 
Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA 
 
5Center for Genetics and Genomics, Facultad de Medicina Clinica Alemana-Universidad del 
Desarrollo, Santiago, 7710162, Chile 
 
6Center for Human Genetics, University of Leuven (KU Leuven), Leuven, 3000, Belgium 
 
7Department of Psychiatry and Behavioral Sciences, and Program in Neuroscience, SUNY 
Upstate Medical University, Syracuse, NY, 13202, USA 
 
8Department of Medical Genetics, Bambino Gesù Hospital, Rome, 00165, Italy 
 
9Department of Pediatrics, Gynecology and Obstetrics La Sapienza, University of Rome, Rome, 
00185, Italy 
 
10Department of Neuroscience, Bambino Gesù Hospital, Rome, 00165, Italy 
 
11Developmental Imaging and Psychopathology Lab, University of Geneva, Geneva, 1211, 
Switzerland 
 
12Department of Psychiatry, Catholic University, Rome, 00153, Italy 
 
13 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine 
and Clinical Neurosciences, Cardiff University, Wales, CF24 4HQ, UK 
14Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, 505095 Ireland 
3 
 
 
15 Department of Forensic and Neurodevelopmental Sciences, King’s College London, Institute 
of Psychiatry, Psychology & Neuroscience, London, SE5 8AF, UK and Behavioural and 
Developmental Psychiatry Clinical Academic Group, Behavioural Genetics Clinic, National Adult 
Autism and ADHD Service, South London and Maudsley Foundation NHS Trust, London, SE5 
8AZ, UK 
 
16Department of Pediatrics, Duke University, Durham, NC, 27710, USA 
 
17M.I.N.D. Institute & Department of Psychiatry and Behavioral Sciences, University of 
California, Davis, CA, 95817, USA 
 
18Virtual VCFS Center, Syracuse, NY, 13206, USA 
 
19School of Psychology, University of Newcastle, Newcastle, 2258, Australia 
 
20Department of Medical Genetics, Aix-Marseille University, Marseille, 13284, France 
 
21Genomics of Health and UDMGC, Son Espases University Hospital, Balearic Islands Health 
Research Institute (IDISBA), Palma de Mallorca, 07120, Spain 
 
22Institute of Medical and Molecular Genetics (INGEMM), University Hospital La Paz, Madrid, 
28046, Spain 
 
23International 22q11.2 Brain and Behavior Consortium:  Table S1 
 
4 
 
24Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and 
Human Behavior, University of California at Los Angeles, Los Angeles, CA, 90095, USA 
 
25Department of Psychiatry and Psychology, Maastricht University, Maastricht, 6200 MD, the 
Netherlands 
 
26Program in Genetics and Genome Biology, Research Institute, and Department of Psychiatry, 
The Hospital for Sick Children, Toronto, Ontario, Canada; Department of Psychiatry, University 
of Toronto, Toronto, Ontario, M5S 1A1, Canada;  Department of Psychiatry, University Medical 
Center Utrecht Brain Center, Utrecht, 3584 CG, the Netherlands 
 
27The Child Psychiatry Unit, Edmond and Lily Sapfra Children’s Hospital, Sackler Faculty of 
Medicine, Tel Aviv University and Sheba Medical Center, Tel Aviv, 52621, Israel 
 
28Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, and 
Children’s Hospital of Philadelphia, Philadelphia, 19104, USA 
 
29Dalglish Family 22q Clinic, Clinical Genetics Research Program and Department of 
Psychiatry, Toronto General Hospital, Centre for Addiction and Mental Health, and the 
University of Toronto, Toronto, M5T 1L8, Canada 
 
30Division of Cardiology, Children’s Hospital of Philadelphia and Department of Pediatrics, 
Perelman School of Medicine, University of Pennsylvania, Philadelphia, 19104, USA 
 
31Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, 
NY, 10461, USA 
5 
 
 
*For correspondence: Bernice.Morrow@einstein.yu.edu 
  
6 
 
Abstract:  
The 22q11.2 deletion syndrome (22q11.2DS) results from non-allelic homologous 
recombination between low copy repeats termed LCR22.  About 60-70% of patients with the 
typical 3 Mb deletion from LCR22A-D have congenital heart disease, mostly of the conotruncal 
type (CTD), while others have normal cardiac anatomy.  In this study, we tested whether 
variants in the hemizygous LCR22A-D region are associated with risk for CTDs based upon 
sequence of the 22q11.2 region from 1,053 22q11.2DS subjects. We found a significant 
association (FDR P<0.05) of the CTD subset with 62 common variants in a single linkage 
disequilibrium (LD) block in a 350 kb interval harboring CRKL. A total of 45 of the 62 variants 
were associated with increased risk for CTDs (OR ranges: 1.64-4.75). Associations of four 
variants were replicated in a meta-analysis of three genome-wide association studies of CTDs 
in cases without 22q11.2DS.  One of the replicated variants, rs178252, is located in an open 
chromatin region and resides in the double-elite enhancer, GH22J020947, predicted to regulate 
CRKL (CRK like proto-oncogene, cytoplasmic adaptor) expression. Approximately 23% of 
patients with nested LCR22C-D deletions, have CTDs and inactivation of Crkl in mice causes 
CTDs, implicating this gene as a modifier.  Rs178252 and rs6004160 are eQTLs of CRKL. 
Further, set-based tests identified an enhancer predicted to target CRKL that is significantly 
associated with CTD risk (GH22J020946, SKAT test P= 7.21×10-5) in the 22q11.2DS cohort. 
These findings suggest that variance in CTD penetrance in the 22q11.2DS population may be 
explained in part by variants affecting CRKL expression. 
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Introduction 
The vast majority of 22q11.2 deletion syndrome (22q11.2DS [MIM: 192430]) patients 
have a 3 million base pair (Mb) hemizygous deletion of chromosome 22q11.2 1.  This syndrome 
is the most frequent chromosomal microdeletion disorder, occurring in 1/4,000 live births 2; 3 and 
1/1,000 fetuses 4; 5.  The 22q11.2DS results from de novo non-allelic homologous recombination 
events between four low copy repeats (LCR) termed LCR22A, B, C and D 6; 7.  Over 85% of 
affected individuals carry a 3 Mb hemizygous deletion between LCR22A-D 8.  However, nested 
proximal (LCR22A-B, 1.5 Mb, 5%; LCR22A-C, 2 Mb, 2%; 6; 7) and distal (LCR22B-D, 1.5 Mb, 
4%; LCR22C-D 0.7 Mb,1%) deletions are present in some individuals with 22q11.2DS 1.  In 
patients with the LCR22A-D and proximal nested LCR22A-B and LCR22A-C deletions, the 
prevalence of congenital heart disease (CHD) is approximately 65% 9; 10.  A somewhat lower 
prevalence (~32%) is observed in patients with distal nested deletions 11-14.  Hence, both nested 
proximal and distal hemizygous deletions are associated with the occurrence of CHD.   
Most 22q11.2DS patients with CHD have conotruncal heart defects (CTDs [MIM: 
217095]15), affecting the development of the cardiac outflow tract including the aortic arch.  
Such defects that occur in 22q11.2DS patients include tetralogy of Fallot (TOF [MIM: 187500]), 
persistent truncus arteriosus (PTA), interrupted aortic arch type B (IAAB), right sided aortic arch 
(RAA) and abnormal branching of the subclavian arteries.  Some have isolated atrial septal 
defects (ASD), ventricular septal defects (VSD) and rarely, other cardiac malformations.  Among 
the known coding genes in the LCR22A-B region, TBX1 (T-box 1 [MIM: 602054]), encoding a T-
box transcription factor 16; 17 is the strongest candidate gene for CTDs, as first suggested by 
gene inactivation studies in mouse models 16-18.  Inactivation of one allele of Tbx1 resulted in 
mild aortic arch anomalies, while inactivation of both alleles resulted in a PTA and perinatal 
lethality 16-18.  Furthermore, missense variants in TBX1 have been found in certain non-deleted 
individuals that partially phenocopied those with 22q11.2DS, implicating TBX1 as a human CTD 
gene 19-24.  There is another gene, CRKL (CRK like protooncogene adaptor protein [MIM: 
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602007]) that has been considered as a candidate.  CRKL, mapping to the LCR22C-D region, is 
also of strong interest because inactivation of both alleles in mouse models results in CTDs with 
late gestational lethality 25.  Of interest, a genetic interaction was observed between Tbx1 and 
Crkl in mouse models, suggesting that they may participate in the same functional pathway 
during embryogenesis 26. 
In contrast to the prevalence of CHD at about 0.5-1% in the general population 27, the 
dramatically elevated CHD risk in the 22q11.2DS population is attributed largely to the presence 
of the hemizygous deletion.  Phenotypic variability, however cannot be fully explained by the 
presence of the 22q11.2 deletion or deletion size and is likely due to the existence of additional 
genetic and/or environmental modifiers.  Identification of modifiers may provide insight into the 
biological mechanism of heart development and disease.  While some insights of the genetic 
architecture of CHD in 22q11.2DS have been gained by array genotyping or whole exome 
sequencing efforts, whole genome sequencing (WGS) methods in large cohorts are needed 28-
33.  The remaining 22q11.2 allele is particularly vulnerable to second hit variants because there 
is only one functional copy of genes that are present.  To test the hypothesis that common 
and/or rare single nucleotide variants (SNVs; including small indels) on the remaining allele may 
be associated with CHD, we used WGS data from 1,053 22q11.2DS subjects, all with the same 
typical 3 Mb LCR22A-D deletion.  We performed a case-control association study using 22q11.2 
subjects with CHD or subtypes within, such as CTDs and controls with 22q11.2DS but with a 
normal heart and/or aortic arch.  Further, to determine whether associations identified in the 
22q11.2DS cohort were also observed in CTD cases from the general population, we 
interrogated existing genome-wide association data from a meta-analysis of CTDs in cases 
without a 22q11.2 deletion 34.  
 
 
Methods 
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Study population 
22q11.2DS cohort 
Recruitment of the study subjects has been previously described 31; 35. Briefly, subjects with a 
known 22q11.2 deletion, existing DNA samples, and approval by institutional research ethics 
boards (Albert Einstein College of Medicine; Committee of Clinical Investigation; CCI#1999-201) 
were recruited in part from the International 22q11.2 Brain and Behavior Consortium 36 (Table 
S1).  A total of 1,595 samples had a clinical diagnosis of 22q11.2DS and carried a laboratory 
confirmed 22q11.2 deletion.  
 
Congenital heart disease phenotypes in the study population  
We obtained cardiac phenotype information from cardiology records including echocardiography 
reports, as previously described 35.  Individuals with missing cardiac records were excluded from 
these analyses. Individuals with the LCR22A-D deletion and any intracardiac or aortic arch 
defect were termed CHD cases.  Individuals with no heart or aortic arch defect, except for those 
with only a patent foramen ovale or VSD and/or ASD that spontaneously closed in infancy 
and/or bicuspid aortic valve, were considered as controls.  For the CTD subset, any of the 
following cardiac defects were considered as CTD cases in the present study: TOF, PTA, IAAB, 
RAA or abnormal origin of the right or left subclavian artery. The difference between CHD and 
CTD cases was that CTD cases excluded isolated VSD or ASD, but both had LCR22A-D 
deletions.  CTD cases can be separated into two different groups based upon differences in 
embryological origin, which are 1) cardiac OFT defects that include TOF, PTA, PS and/or PA 
and 2) aortic arch defects or arterial branching defects from the aortic arch that include RAA, 
IAAB or other aortic arch defects such as abnormal origin of the right subclavian artery.  We 
also performed other sub-phenotype comparisons as described.  
 
Complete sequencing of the 22q11.2 region and quality control measures  
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WGS with a median depth of 39-fold was performed on 1,595 subjects as part of the 
International 22q11.2 Brain and Behavior Consortium 36.  Briefly, samples were sequenced 
using the Illumina HiSeq X Ten for the first 100 samples and the Illumina HiSeq 2500 platform 
for all other samples at Hudson Alpha Corp. (Huntsville, AL).  Sequence reads were mapped to 
genome build hg38 (December 2013; GRCh38/hg38) with PEMapper (90% stringency for 
2x100bp reads and 95% stringency for 2 x 150bp reads; 37). Deletion sizes were confirmed by 
the coverage at the 22q11.2 region.  Variants on the remaining 22q11.2 allele (LCR22A-D 
region; chr22: 18115819-21432004, hg38) were called by PECaller in haploid mode.  Variants 
were called if > = 90% of the variants at the site had a posterior probability >=95%.  Variants 
were removed if Hardy-Weinberg Equilibrium (HWE) P value were <1.0 ×10-5.  Exclusion was 
based upon the quality control (QC) results of the dataset from the genome-wide diploid 
variants.  Samples of relatives and mismatched gender or samples with poor-quality sequence 
were removed.  For all samples with the LCR22A-D deletion, variants with a genotype call rate 
of < 0.95 and monomorphic variants were removed.  Variants within LCR22 regions were 
removed because of their repetitive nature.  
 
Principal Component Analysis 
Principal component analysis (PCA) was conducted based on the dataset of genome-wide 
diploid variants as well as Hapmap 3 r3 (International HapMap project Phase III Release 3) data 
using plink/1.90b. First, shared variants in this dataset and the Hapmap 3 r3 dataset were 
extracted and combined into one dataset.  Of note, variants with A>T, T>A, G>C and C>G allele 
types were removed to avoid any potential strand flip issues.  Second, variants with minor allele 
frequency < 0.05 and variants in sex chromosome were excluded.  After this, autosomal 
common variants were pruned using the –indep function to ensure only independent variants 
were used for PCA.  Lastly, PCA was conducted using the –pca function.  European Caucasian 
ancestry of the subjects was determined by the Multidimensional Outlier Detection method as 
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implemented in SVS Golden Helix software. Firstly, a median centroid vector was calculated as 
[median (column1), median (column2), median (column3)] based on top 3 PCs for all the 
samples plus Hapmap Caucasian (CEU) and Tuscans in Italy (TSI) samples (combined, 
referred to as Caucasian). A distance score was then calculated for each sample as follows: 
 
The outlier threshold is calculated as follows: 
  
Where Q3 and IQR are the third quartile and inner quartile range of each sample (1…N) and M 
is a user-specified multiplier; in this study, 2 was adopted.  Outliers of Caucasian samples were 
examined in the scatter plot of PC1 versus PC2; samples clustered with HapMap Gujarati 
Indians in Houston, Texas (GIH) and Mexican ancestry in Los Angeles, California (MEX) 
population were grouped as Hispanics. Populations dispersed towards Yoruban in Ibadan and 
Nigeria (YRI) Africans were grouped as African-admixed populations.  PCA was further 
conducted in the three subpopulations respectively, in order to obtain the top several PCs that 
can be used as covariants to adjust for possible population stratification in the stratified 
analyses.  
 
SNV-based analyses 
Logistic regression analyses for common variants were conducted in all 1,053 samples as well 
as the Caucasian, African-admixed, and Hispanic subsets, respectively, with adjustment of sex 
and corresponding number of PCs for CHD, CTD, TOF and TOF-PTA-IAAB risk.  False 
discovery rate (FDR) was employed to correct for multiple testing issues.  For rare variants, we 
conducted the Fisher’s exact test in the Caucasian population. Considering most genome-wide 
association studies adopted a suggestive significant threshold at 1.0 ×10-5 for 2.0×106 to 
1.0×106 variants, we set the suggestive significant threshold for this study of a few thousand 
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variants at P =1.0×10-3 for both common and rare variants. SNV based analyses were done 
using plink/1.90 38. For the top variants in the LCR22C-D region with evidence of association 
with CTD risk in the 22q11.2DS cohort, we interrogated existing data from a meta-analysis of 
three published genome wide association studies (GWAS) of CTDs in individuals without a 
22q11.2 deletion 34.  
 
Functional annotation filtering of rare loss of function, high-confidence deleterious 
missense and splicing variants 
Variants that passed QC were annotated for possible biological function using Bystro 39, snpEff 
40 and dbNSFP 41.  We adopted the definition of loss of function (LoF) variants as previously 
described 42.  Briefly, LoF variants included those with any predicted indel-frameshift, stop gain, 
splice donor, splice acceptor, stop loss, start loss and low frequency variants, typically with an 
alternate allele frequency (AAF) less than 0.001 in gnomAD (The Genome Aggregation 
Database). These would be highly damaging variants.  Only consistent predictions for LoF 
variants by Bystro and snpEff were included.  As an ensemble annotation tool, Bystro also has 
additional annotations for possible function, including phastCons and phyloP, Combined 
Annotation Dependent Depletion score (CADD; 43 and AAF of gnomAD 39.  High confidence 
damaging missense (D-Mis) variants are defined by prediction as “damaging” or “deleterious” or 
passing the suggested threshold for scores by at least half of the 29 algorithms compiled in 
dbNSFP for SNVs (including SIFT 44, SIFT4G 45, Polyphen2-HDIV 46, Polyphen2-HVAR 46, LRT 
47, MutationTaster2 48 and additional algorithms 41).  Probabilities of SNVs affecting splicing were 
annotated by ada and random forest scores by dbscSNV (database for splicing consensus 
variants), which is a companion database in dbNSFP (database for functional prediction for non-
synonymous variants).  High confidence damaging splicing variants (D-splicing variants) 
included in this study were those that passed the suggested threshold of both algorithms (0.6 of 
the 0 to 1 range).  Variants in evolutionarily conserved regions were defined as those with both 
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phastCons and phyloP values in the top quantile.  Variants that mapped to multiple transcripts 
and therefore had multiple annotations required prioritization of the RefSeq site type that follows 
priority of exon > UTR > intron > intergenic and the RefSeq exonic allele function following a 
priority of indel-frameshift = start loss = stop gain = stop loss > indel-nonFrameshift > 
nonsynonymous > synonymous. 
LINSIGHT measures potential non-coding variants that have effects on fitness based on 
primate evolution 49.  The LINSIGHT score of top associated variants in the LCR22C-D region 
were downloaded from the UCSC Genome Browser. Expression quantitative trait loci (eQTLs) 
of CRKL were identified in the GTEx database portal 50.  Variants were evaluated in ATAC-seq 
data of open chromatin regions during differentiation from human induced pluripotent stem cells 
(hiPSCs) and human embryonic stem cells (hESCs) to early cardiomyocytes (GSE85330 51).  
 
Enrichment analyses of rare variants 
Based on variant annotation results, rare variants (alternative allele frequency, AAF<0.01 in the 
gnomAD database) that fell into 14 categories were extracted, including all LoF, CADD score 52 
over 30, CADD score over 15, missense with CADD>15, all missense, synonymous with 
CADD>15, all synonymous, all exonic, all in UTR regions, all intronic, all in promoter regions (2 
kb both upstream and downstream of transcriptional start site, TSS), in double elite 
enhancers53, in conserved regions and variants in non-coding RNAs (ncRNAs). Double elite 
enhancers are defined as those that have two or more functional genomic evidence sources for 
being a regulatory element (e.g. chromatin conformation assays) and have associations with a 
gene target that are supported by two or more functional genomic methods (e.g. expression 
quantitative trait loci) 53. For these 14 categories of rare variants, we compared the average 
number that mapped to each category in cases to the average number in controls. The 
significance of enrichment of any of the categories in CTD cases versus controls were accessed 
by 10,000 label-swapping permutation testing of case-control labels. 
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Set-based analyses 
Set-based analyses were conducted for common and rare variants, respectively. Sets in the 
LCR22A-D region including RefSeq genes between the TSS and transcriptional termination site 
(TTS) end as well as both 2 kb upstream and downstream, promoter regions (both 2 kb 
upstream and downstream of the TSS), and the double elite set of curated high-confidence 
enhancers in the GeneHancer database 53. All detailed information about the sets were 
downloaded from the UCSC Genome Browser (assembly hg38). There are 72 genes in the 3 
Mb region including known or predicted coding as well as non-coding genes, and therefore 72 
promoters, as well as 96 double elite enhancers.  Therefore, the Bonferroni multiple correction 
threshold for the set-based test P value was set at 2.1×10-4.  Suggestive significant threshold 
was set at P=1.0×10-3.  We used the burden test 35 to evaluate if there were any rare variants in 
any set that were enriched and we tested whether the effects are in the same direction.  We 
used SKAT to test for common variants to consider the situation where a large fraction of the 
variants in a region are non-causal or the effects of causal variants were in different directions 
54.  The set-based tests were implemented in the SKAT R package 55. 
 
 
Results 
22q11.2DS cohort and study design 
The study cohort consisted of 1,053 individuals with 22q11.2DS and WGS data, who had a 3 
Mb LCR22A-D deletion (Figure 1A and Table S2).  A total of 14,158 SNVs within the LCR22A-D 
region from WGS passed quality control measures and were used in the downstream analyses 
(Table S3).  Demographic characteristics of the study cohort and frequency of various cardiac 
defects among 1,053 subjects is listed in Table 1. The conotruncal region of the heart contains 
the aorta, pulmonary trunk and arterial branches and is shown in Figure 1B.  Among the 1,053 
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individuals with 22q11.2DS, 584 (55.5%) had a diagnosis of CHD, 424 (40.3%) had a CTD, 105 
(10.0%) had an isolated VSD and 55 (5.2%) had an isolated ASD (Table 1; Figure 1C).  The 
most common phenotype among those with a CTD was TOF (n=194; 18.4%; Table 1; Figure 
1C).  The remaining 469 (44.5%) individuals with the LCR22A-D deletion that had a normal 
heart and aortic arch and were designated as controls (Table 1; Figure 1C).   
Ancestry of the 22q11.2DS cohort determined by PCA is shown in Figure 2A and listed 
in Table 1.  A total of 790 of the 1,053 subjects were of European descent, while the rest were 
of African-admixed (n = 161), or Hispanic (n = 102) descent as indicated (Figure 2A; Table 1).  
As shown in Figure S1, the top five (n = 1,053), four (n = 790 CEU), four (n = 104 Hispanics), 
and five (n = 161 African-admixed) PCs accounted for the majority of the population variance 
and hence were used as covariates for logistic regression analyses of common variants among 
all subjects and stratified analyses for the three subpopulations, respectively.  
The frequency distribution of the 14,158 variants that passed quality control is presented 
in Figure 2B.  There were 9,821 rare variants with an AAF<0.01 and 4,337 low frequency and 
common variants. The low frequency variants were grouped into common variants for all 
analyses, for simplification, they are referred to herein as one group, named common variants 
throughout this study.   
The study design is presented in Figure 3.  Briefly, haploid variants in the 22q11.2 region 
were classified into common variants, rare variants and the most damaging category of rare 
variants including LoF and deleterious missense and splicing variants. Then different analytical 
strategies were applied to the three groups of variant categories that will be described in detail 
in the next sections.  
 
SNV-based common variant analyses 
We performed an association study of common variants, comparing  584 CHD cases to 
469 controls with 22q11.2DS and found suggestive evidence for association with several 
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variants in the LCR22C-D region (Figure S2A). We repeated these analyses, restricting the 
cases to include only those with CTDs (N=424) and identified significant associations in the 
same region.  The association signal was in a cluster of 62 SNVs in a 350 kb region largely 
within LCR22C-D (chr22: 20607741-2095814; hg38; Figure 4A and 4B) that are in strong LD 
(Figure 4C).  The SNVs have an AAF >0.05 (Figure 4D), with P values ranging from 10-3 to 
2.59×10-5, of which 45 passed FDR correction from logistic regression analyses (Table S4).  
This region contains four functional genes that include PI4KA (Phosphatidylinositol 4-kinase 
alpha [MIM: 600286]), SERPIND1 (Serpin family D member 1 [MIM:142360]), SNAP29 
(synaptosome associated protein 29 [MIM: 604202]) and CRKL as shown in Figure 4E.  
Variants that passed FDR correction were highlighted in red, for all CTD samples (Figure 4A) 
and for the Caucasian subset (Figure 4B), respectively.  These variants were not significantly 
associated with CTDs in the African-admixed or Hispanic population, possibly because the 
sample sizes were very small (Figure S2B-C).  Of note, none of the SNVs in the coding and 
non-coding regions of TBX1 showed association with risk for CTDs (all P>0.05) in any 
subpopulation (Figure 4B and S2B-C).  
We next performed phenotype subset analyses.  The difference between the CHD and 
CTD categories was the inclusion of isolated VSD or ASD in the CHD category. Logistic 
regression analyses for isolated VSD or ASD showed that they do not contribute to the 
association signals between LCR22C-D (Figure S2D-E).  In fact, adding the isolated VSD or 
ASD categories to the analysis reduced the association signals (Figure S2A), suggesting that 
they have different risk factors in the 22q11.2DS population.   
We next tested for evidence whether association differs within subgroups, with the 
caveats that group sizes vary.  We first compared the subgroup of TOF cases with the same 
controls and then the subgroup that included TOF, PTA or IAAB, to controls, in the Caucasian 
subpopulation.  Variants with a P value <1.0 ×10-3 for all of the categories were compiled that 
included variants occurring from two or more subgroups, with the smallest P value, totaling 69 
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variants in LCR22C-D region Table S4).  We did not observe a difference in the association test 
for the TOF or combined TOF-PTA-IAAB versus the CTD categories and the same controls, 
suggesting that these subsets share a similar genetic risk.   
The cardiac OFT forms from the second heart field mesoderm and neural crest 
mesenchymal cells, while the aortic arch and arterial branches develop from the pharyngeal 
arch arteries containing vascular endothelium that is mesoderm derived as well as smooth 
muscle cells that are neural crest derived 56; 57.  The CTD category consists of subjects with 
cardiac OFT defects and/or aortic arch defects.  Because of their different embryological origins, 
we compared the two.  As shown in Figure S3, the group with cardiac OFT defects (Figure S3A) 
contributes much more to the strength of the association signal in the 350 kb region, with the top 
variants passing FDR for multiple testing correction, as compared to the group with aortic arch 
defects (Figure S3B). This result supports the findings that these have different developmental 
and anatomical origins, therefore their genetic control may also be distinct. 
 
Set-based analysis for common variants and odds ratios 
We performed a set-based SKAT test to determine the genetic risk of genes, promoters and 
enhancers focusing on CTDs in the 22q11.2DS population.  Results from the set-based test for 
common variants is presented in Figure 5A and Table S5.  We found the gene, SERPIND1 and 
one double elite enhancer, GH22J020946, were significantly associated with CTD risk after 
Bonferroni correction (Figure 5A).  Data on chromatin regulation and chromatin interactions are 
shown in Figure 5B.  These analyses indicate significant interactions between the four coding 
genes mapping to the 350 kb interval (Figure 5C).   
 Double elite enhancers have functional genomic evidence for regulatory activity and for 
particular gene targets 53.  There are eleven double elite enhancers in the 350 kb region 
(GH22J020748, GH22J020775, GH22J020855, GH22J020866, GH22J020883, GH22J020916, 
GH22J020936, GH22J020939, GH22J020940, GH22J020946, GH22J020947) as indicated in 
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Table S6.  These double elite enhancers have not been assayed as of yet, for function in human 
or mouse cardiac development but are of interest as harboring non-coding common variants, 
such as the double elite enhancer, GH22J020946.  
 We examined the odds ratio (OR) of the SNVs in the 350 kb region to determine the 
individual and overall risk of the variants.  The distribution of OR as well as the corresponding 
95% CIs were plotted in this 350 kb region (Figure 5D-E).  Most of the variants were associated 
with increased odds of CTDs with a median OR of 2.96, ranging from 1.64 to 4.75, while 
alternate alleles of 3 variants were associated with an OR less than 1 (OR range: 0.48 from 
0.52) (Table S4).   
 
Replication of the top associated variants based in three different CTD cohorts without a 
22q11.2 deletion 
Of the 69 top associated variants, 49 were included in a meta-analysis of three GWAS of CTDs 
in non-deleted individuals 34.  Four of these variants had meta-analysis P values <0.05 and the 
direction of association was the same as observed in the 22q11.2 deleted cohort (Table 2).  
Three of these SNVs, rs165912, rs6004160 and rs738059, are in complete LD (i.e. R2=1, based 
on Hapmap r3 Caucasian data) and were similarly associated with CTDs (OR=1.10, 95% CI, 
1.00-1.21, meta-P=0.04) in the meta-analysis.  Among the three, rs6004160 is an eQTL of 
CRKL.  The most significantly replicated SNV, rs178252 (OR=1.16 [1.04-1.30], meta-P=0.006), 
is also an eQTL of CRKL (Table S7, Figure 5E).  The SNV, rs178252, resides in the double elite 
enhancer, GH22J020947 (10 kb in sequence), and one of the top predicted targets is CRKL, 
based on the GeneHancer database (Figure 5B). Moreover, the SNV, rs178252, is one of two 
variants among the 69 that maps to open chromatin regions51 as shown in Table 2, Figure S4 
and Figure 5E.  
 
Functional annotation of association signals in the LCR22C-D region 
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One of the challenges is to find possible causal variants in the associated 350 kb region 
because of the presence of a large LD block.  To identify possible functional variants, CADD, 
LINSIGHT and phastCons scores were generated for the 69 SNVs.  Detailed associations of the 
69 variants are presented in Table S4.  Of note, 12 of the SNVs are eQTLs of CRKL as 
identified in GTEx data (Muscle-Skeletal), suggesting that they may be functional.  Two SNVs 
reside in an open chromatin region based upon data from human stem cells51 (Figure S4).  All 
except one of the 69 SNVs are in non-coding sequences.  The one coding variant, rs165854, 
has a low CADD score of 5.97, indicating it is less likely to be causal.  The AAF of SNVs in both 
this 22q11.2DS cohort and that of the gnomAD database were plotted in Figure 4D. Variants 
have similar AAFs in both datasets, indicating the high quality of our data and that subsets of 
the variants have similar AAFs in either dataset, which is evidence that those variants are in 
high-to-complete LD. 
 
Enrichment analyses of rare deleterious variants in the 22q11.2DS cohort 
We also tested the hypothesis that rare variants might alter risk for CHD or CTDs in the cohort.  
Three rare LoF variants, six high-confidence D-Mis variants and four high confidence D-splicing 
variants were identified in the remaining allele of 22q11.2 (Table S8).  Of note, none of these 
LoF, D-Mis and D-splicing variants were located in TBX1 or CRKL 1. Those variants occurred in 
nine CHD cases, seven in the CTD subset and ten in controls, with no enrichment in CTD 
cases, indicating that it is unlikely that predicted damaging variants in the 22q11.2 region could 
account for CHD or CTD risk and explain the phenotypic heterogeneity in this population.  No 
significant enrichment of rare variants in the Caucasian subpopulation in any of the 14 most 
functional plausible categories was identified (all empirical P>0.05; Figure S5).  When taken 
together, it is less likely that rare coding variants in this region influence risk for CHD or CTDs in 
individuals with 22q11.2DS. 
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SNV-based Fisher’s exact test and set-based burden test for analyses for rare variants in 
the Caucasian population 
We then tested the hypothesis that the association signal in the 350 kb region in the LCR22C-D 
interval for CTDs is driven by rare variants in the same region.  Due to issues related to 
population stratification for rare variant association analysis, we focused on the largest sized, 
Caucasian population.  Fisher’s exact test was run in samples from 669 Caucasian subjects 
including those with CTDs and controls.  The distribution of rare variants, individually, between 
CTD cases and controls was not significantly different (Figure S6).  Moreover, there was no 
significant difference between CTD cases versus controls for the joint effect of rare variants 
when aggregated into genes, promoter and enhancer regions based on burden tests (Figure 
S7).  Of note, the burden test had a P > 0.05 for both TBX1 and CRKL.  These results indicate 
that it is less likely that rare variants account for the significant association found for common 
variants of CTD risk in LCR22C-D.  Therefore, the association signals of common variants are 
less likely driven by rare variants, pointing to the possibility that common variants might drive 
the signal that was observed.   
 
 
Discussion 
In this report, we found that common variants in a 350 kb region on the remaining allele, largely 
within the LCR22C-D interval, are associated with moderate increased risk (OR range: 1.6-4.8) 
for CTDs in individuals with the typical 3 Mb 22q11.2 deletion.  Based upon complete sequence 
data, this association was not driven by rare variants individually or jointly in the same region, 
suggesting that associated common variants are amongst the top causal variants. 
 
Different 22q11.2 deletions and similar phenotypes 
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Individuals diagnosed with 22q11.2DS have highly variable clinical phenotypes.  One of the 
early prevailing hypotheses was that this clinical variation was due to differences in deletion 
sizes resulting in haploinsufficiency of different genes.  While early data suggested that the 
LCR22A-B region was the critical region for the syndrome 6; 7; 58-60, patients were identified 
recently with non-overlapping LCR22B-D and C-D deletions 11; 13.  Despite having non-
overlapping deletions, these individuals had a similar CTDs with half the frequency 14.  The 
existence of patients with LCR22B-D or C-D deletions and CTDs, coupled with the data 
presented in this report, support the likelihood that the LCR22C-D region contains modifiers of 
CTD risk.  Individuals with the LCR22A-C deletion have a similar frequency of CTDs as in the 
LCR22A-B or LCR22A-D region.  Thus, we suggest that CRKL acts as a risk factor, but that the 
22q11.2 region is quite complex and understanding the biology of the region is still in its infancy.  
 
Evidence that non-coding variants in CRKL might modify the phenotype in 22q11.2DS  
We identified a significant association between common variants in a 350 kb interval within the 
LCR22C-D region.  Since the variants in the 350 kb region are in LD, it is not possible to rule out 
individual genes without further functional annotation.  There are four known protein coding 
genes that map to the interval: PI4KA, SERPIND1, SNAP29 and CRKL.  The PI4KA gene 
product functions as a critical enzyme in the metabolism of plasma membrane 
phosphoinositides by catalyzing one of the early steps of membrane lipid formation 61.  
Inactivation of PI4KA in the mouse results in early embryonic lethality and it is therefore an 
essential gene for embryonic development 62.  Recessive mutations in PI4KA were discovered 
in one family in which three fetuses carrying compound heterozygous mutations had 
polymicrogyria and cerebellar hypoplasia as well as other malformations but did not indicate that 
there were cardiovascular anomalies present 63.  In studies in zebrafish, knockdown of pi4ka by 
morpholino injection resulted in abnormal fin development, shortened body axis and pericardial 
edema, which could implicate functions in the heart 64.  Thus, it is not known if non-coding 
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variants in the locus could alter PI4KA expression and thus, could increase risk for CTDs.  As 
mentioned above, SERPIND1 encodes Heparin co-factor II, which inhibits thrombin activity.  
Inactivation of SERPIND1 in humans causes excess thrombin and deep vein thrombosis 64-66.  
In one report, Serpind1 null mutant mice were found to survive in normal Mendelian ratios 67 and 
in another report of a similar null mutant, they were embryonic lethal and had vascular 
remodeling defects but they did not have cardiac developmental defects 68.  The SNAP29 gene 
product is located in the cytoplasm and is involved in intracellular membrane vesicle fusion and 
membrane trafficking 69.  Recessive mutations in SNAP29 in humans cause cerebral 
dysgenesis, neuropathy and skin conditions, termed CEDNIK syndrome [MIM: 609528] 70.  
Among these four genes, CRKL is the most likely candidate gene for which altered expression 
by non-coding variants on the remaining allele of 22q11.2 might influence risk to CTDs. 
 The top associated variants identified in this study lie in putative regulatory regions of 
CRKL, as described above.  Crkl is a ubiquitously expressed gene and mouse model data 
suggests that it functions in neural crest cells within the pharyngeal apparatus for cardiovascular 
development 25.  Inactivation of both alleles of Tbx1 or Crkl in the mouse results in a similar 
spectrum and range of CTDs 16-18 and they genetically interact during embryogenesis 26.  The 
connection between these genes is based upon the hypothesis that Tbx1 acts upstream and 
Crkl acts downstream in a FGF8 (Fibroblast growth factor 8 [MIM: 600483]) through the MAPK 
(Mitogen-activated protein kinase) signaling pathway, which is critically important for heart, 
aortic arch and arterial branch formation 71.  Therefore, there is precedence from mouse genetic 
studies that CRKL may act as a modifier and variants that might reduce expression of CRKL 
would increase risk for CTDs.  One question is whether CRKL is sensitive to altered gene 
dosage.  An allelic series generated in the mouse showed that Crkl is partially sensitive to 
altered gene dosage in embryonic development 14.  Various cardiovascular anomalies were 
identified that included CTDs 14. 
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Strengths and limitations in examination of sequence in the 22q11.2 allele 
The availability of WGS is a strength of the study, since good coverage of the interval was 
obtained.  Although the sample size was large for a rare condition such as 22q11.2DS, we 
evaluated several thousand variants and, given statistical correction for multiple comparisons, 
power was still quite low for variants of low effect size. Consequently, we may have missed true 
associations.  Fine-mapping to identify so-called causal variants is exceedingly difficult because 
the variants of interest were in high-to-complete LD.  With the availability of data sources such 
as GTEx and GeneHancer, we found that top associated variants may affect expression levels 
of CRKL. Another strength lies the availability of summary P value statistics from non-deleted 
subjects with CTDs that provided supportive data.  Variants identified in this report can be 
tested in the future by functional validation and in vivo studies.  Examination of chromatin 
structure by high throughput chromatin conformation capture (Hi-C) implies that this 350 kb 
region is within a single topological associated domain 72.  On the other hand, a recent study 
reported that local and global chromatin interactions were altered dynamically in a multilayered 
fashion in 22q11.2 lymphoblastoid cell lines as compared to control cell lines without deletion 72.  
Therefore, the deletion might affect chromatin interactions outside this interval and other genes 
could serve as modifiers.  It is therefore possible that a regulatory element within the 350 kb 
region could alter TBX1 expression or that of another gene elsewhere on 22q11.2.  
Nonetheless, the fact that patients with LCR22B-D and C-D deletions have CHD at 20-30%, 
suggest that this region is critically important as a potential modifier of cardiac development in 
22q11.2DS.  
Conclusions:  In this report, we found that a cluster of common SNVs in the LCR22C-D region 
on the remaining allele of 22q11.2 is associated with the risk for CTDs in subjects with 
22q11.2DS.  Haploinsufficiency of this region alone is associated with CTDs, and when taken 
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together with mouse genetic studies, implicate, mostly plausibly, CRKL as a possible target of 
non-coding putative regulatory variants. 
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Figure legends: 
 
Figure 1. The 22q11.2 deletion syndrome cohort. (A) Illustrative map of the 22q11.2 region depicting 
the locations of LCR22A, B, C and D (box) and the 3 Mb deleted region (gray box) downstream from the 
centromere (dark gray circle).  (B) Heart in mammals indicating the aortic arch, pulmonary trunk (PT) and 
branches of the aortic arch. RV, right ventricle; LV, left ventricle.  RCCA and LCCA, right and left common 
carotid artery; RSA and LSA, right and left subclavian artery; IA, innominate artery (C) Pie chart of cardiac 
and aortic arch phenotypes including 469 with a normal heart and aortic arch (gray) and phenotypic 
breakdown of 424 subjects that comprise the cohort with CTDs.  Among the 424, 194 had tetralogy of 
Fallot (TOF; green), 79 had a right sided aortic arch (RAA; dark blue), 56 had interrupted aortic arch type 
B (IAAB; yellow), 34 had a persistent truncus arteriosus (PTA; dark gray), 28 had pulmonary stenosis or 
pulmonic atresia (PS/PA; light blue) and 33 had other aortic arch defects such as abnormal of the right or 
left subclavian artery in the absence of other cardiac or aortic arch anomalies. 
 
Figure 2. Ethnicity and constituency of variants in the 1,053 22q11.2DS cohort.  (A) Scatter plot of 
the first PC (EV=100.97) versus the second PC (EV=52.41) calculated from PCA based on common 
independent shared variants in the 22q11.2DS cohort (aqua color) and HapMap 3 r3 samples 
(International HapMap project Phase III Release 3, including 1,397 individuals from 11 populations across 
the globe; colored based upon the population).  ASW, African ancestry in Southwest USA; CEU, Utah 
residents with Northern and Western European ancestry ; CHB, Han Chinese in Beijing, China; CHD, 
Chinese in Metropolitan Denver, Colorado; GIH, Gujarati Indians in Houston, Texas; JPT, Japanese in 
Tokyo, Japan; LWK, Luhya in Webuye, Kenya; MEX, Mexican ancestry in Los Angeles, California; MKK,  
Maasai in Kinyawa, Kenya; TSI (T): Tuscan in Italy; YRI (Y), Yoruban in Ibadan, Nigeria (West Africa). (B) 
Frequency distribution of 14,158 variants that passed QC measures. There are in total 9,821 rare variants 
with AAF<0.01, 1,380 low frequency variants (AAF between 0.01-0.05) and 2,957 common variants 
(AAF >0.05). 
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Figure 3. Data analyses flowchart of this study. Common variants and rare variants were determined 
by the alternate allele frequency (AAF) of individuals in the gnomAD database at the threshold of 0.01. 
 
Figure 4.  Regional plot of logistic regression analyses identifies significant association to a 350 
kb LCR22C-D interval.  (A, B) Regional plot for common variants versus CTD risk in remaining allele of 
22q11.2 with adjustment of sex and top five PCs in 893 samples (A) and top four PCs in 669 Caucasian 
samples (B). Variants in TBX1 and CRKL loci are indicated (green).  Grey blocks represent LCR22A, B, C 
and D in the 22q11.2 region.  Blue horizontal lines represent threshold of suggestive significant 
association for multiple testing at 1.0×10-3.  Two vertical red dashed lines denote top associated variants 
(chr22:20607741-20958141 in Genome Assembly, hg38).  Red bar indicates LD block.  Variants in red 
survived false discovery rate (FDR) for multiple testing correction.  (C) LD structure in the Caucasian 
population based on HapMap data in the top associated region in the UCSC genome browser. (D) Bar 
plot of the alternate allele frequency (AAF) of top variants in the 22q11.2DS population (red) as well as in 
the gnomAD database (aqua) in the top associated region. (E) Snapshot of the UCSC Genome Browser 
indicating the genomic interval of 22q11.2, Segmental Duplication track indicating LCR22C and the 
RefSeq gene alignment in the top associated region.  
 
Figure 5. Set-based SKAT test for common variants identifies non-coding variants in gene 
regulatory regions in the 350 kb LCR22C-D region.  (A) SKAT test with adjustment of sex and top four 
PCs was applied to common variants in the cohort of 669 Caucasian samples. Set includes all 72 
predicted coding and non-coding genes (blue; between transcriptional start site-TSS and transcriptional 
termination site-TTS plus 2 kb both upstream and downstream) between LCR22A-D, 72 putative 
promoters of these genes (green; both 2 kb upstream and downstream of TSS) and 96 curated double 
elite set of enhancers (red) in the 22q11.2 region.  Pink background highlights TBX1 and CRKL. Two blue 
horizontal lines represent suggestive and Bonferroni corrected significant thresholds for multiple testing, 
at 2.5×10-3 and 2.1×10-4, respectively.  Two vertical dashed red lines denote where the top associated 
signals reside from logistic regression analyses (chr22: 20607741-20958141, in hg38).  Arrows depict 
significant gene (SERPIND1) and enhancer (GH22J020946).  Four gray blocks represent LCR22A, B, C 
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and D.  (B) Snapshot of the UCSC Genome Browser in hg38 assembly showing the genomic context in 
the 350 kb top associated region including Segmental Duplication track (LCR22C), RefSeq genes, 
H3K4Me3 (promoter) and H2K27Ac (enhancer) marks from cell lines, double elite set of enhancers (gray) 
and promoters (red), indication of TSSs, and the interactions between enhancers and genes in this 
region.  Arrows point to the double elite enhancer and gene found above (A).  Note that there are five 
double elite enhancers regulating CRKL (GH22J020947, GH22J020946, GH22J020940, GH22J020939, 
GH22J020936) indicated below the regulatory region interactions. (C) Gene alignment in the top 
associated region based on RefSeq gene track in UCSC genome browser. (D, E) Distribution of ORs of 
69 top associated variants (P < 1.0×10-3); of which seven variants are eQTLs of CRKL (red dots in E);  
three empty circles and one empty triangle in E, represent variants of which the association with CTD risk 
was also found in the CTD cohorts without  22q11.2 deletion; two closed black triangles in E, denote 
variants located in an open chromatin region. Of note, rs178252 includes all of the three features.  
Enlarged image is below. 
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Table 1. Demographic and clinical characteristics of the 22q11.2DS cohort 
Variables  No. (%) for categorical variables for all 1,053 samples 
No. (%) for categorical variables for 893 
main studied CTD case-control cohort 
Gender    
   Male 512 (48.6%) 430 (48.2%) 
   Female 541 (51.4%) 463 (51.8%) 
Deletion type    
   AD 1,053 (100%) 893 (100%) 
CHD statusa    
   Normal heart 469 (44.5%) 469 (52.5%) 
   CTD 424 (40.3%) 424 (47.5%) 
   CHD 584 (65.0%)  
   TOF-PTA-IAAB 284 (26.9%)  
   TOF 194 (18.4%)  
   ASD alone 55 (5.2%)  
   VSD alone 105 (10.0%)  
Population origin     
   Caucasian 790 (75.2%) 669 (74.9%), 312:357 ccc 
   AAb and admixed 161 (15.3%) 135 (15.1%), 68:67cc 
   Hispanic 102 (9.7%) 89 (10.0%), 44:45 cc 
aDefinition of CHD phenotypes: patients are coded as cases for the specific CHD categories if they 
satisfied the corresponding definitions. Control are those with no heart or aortic arch anomalies. CTD, 
conotruncal heart defect; TOF, Tetralogy of Fallot; PTA, persistent truncus arteriosus; IAAB, 
interrupted aortic arch. bAA, African-admixed. ccc, stands for no. of CTD cases and controls. 
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aRelative risk based on comparison of heterozygote to common homozygous genotypes. bLikelihood ratio test comparing full model with inherited genotype modeled as an additive 
effect and maternal genotype unrestricted, to the model with just the unrestricted maternal genotype. cmeta-analyses of three CTD cohorts without 22q11.2 deletion. dcc, case-control. 
eeQTL data was downloaded from GTEx. fDetermination of whether the variants reside in open chromatin region is based on ATAC-seq data from human induced pluripotent stem 
cells and human embryonic stem cells51
Table 2. Association results of four replicated variants in three independent CTD cohorts without  22q11.2 deletion and meta-analysis, as well as primary results in the 22q11.2DS cohort 
Datasets 
 
No of 
subjects 
rs178252 (G>A) rs165912 (C>T) rs6004160 (G>A) rs738059 (G>A) 
AAFa OR (95%CI)b P value AAF OR (95%CI) P value AAF OR (95%CI) P value AFF OR (95%CI) P value 
22q11.2DS cohort 469:424 ccd 0.720 1.67(1.24-2.25) 6.90E-4 0.393 1.62(1.23-2.14) 6.03E-4 0.939 1.65(1.25-2.18) 3.66E-4 0.392 1.64(1.24-2.16) 4.80E-4 
Meta-analysisc   1.16 (1.04-1.30) 0.006  1.10 (1.00-1.21) 0.04  1.10 (1.00-1.21) 0.04  1.10 (1.00-1.21) 0.04 
eQTL of CRKLe  Y N Y N 
Open chromatin 
regionf  Y N N N 
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